Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
We greatly appreciate the comments made by Leslie-Mazwi et al.1 As they mentioned, the lack of a 90-day modified Rankin Scale (mRS) was a major limitation of our study. In order to share our first-hand experience as soon as possible during the pandemic, we only reported 7- day outcomes. However, the 90-day follow-up was pre-planned, as we stated in response to peer review comments. As shown in figure 1, a good clinical outcome (mRS ≤2) was seen in 52.9% (9/17) in the pandemic group compared with 39.4% (13/33) in the pre-pandemic group; this difference was not statistically significant (p=0.361). No significant difference was identified for either 90-day mortality (4/17 (23.5%) vs 5/33 (15.2%), p=0.732) or 90-day National Institutes of Health Stroke Scale score (4, IQR 1–12 vs 8, IQR 4–10; p=0.320) in the pandemic and pre-pandemic groups, respectively. However, the small sample size may partially account for this equivalence, therefore future prospective multicenter studies are warranted.
Contributors All authors of this work met the International Committee of Medical Journal Editors criteria for authorship and made substantial contributions to the conception and design, acquisition of data, analysis and interpretation of data, drafting, critical revising, and final approval of the manuscript.
Funding This work was supported by the National Key Research and Development Project (2016YFC1301703) and the Beijing Scientific and Technologic Project (D161100003816002).
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.